A disadvantage of S100B as a tumor marker of malignant melanoma is the possible loss of S100B expression during malignant progression which would disrupt the dependency of measured serum S100B levels to the cell loss fraction and immunologic cell death (see Figure 2) [42]. Here, S100B is linked to neoplasm.